Multiple pathways are involved in the oral absorption of BMS-262084, a tryptase inhibitor, in rats: Role of paracellular transport, binding to trypsin, and P-glycoprotein efflux

Journal of Pharmaceutical Sciences

Volumn 94, Issue 5, 2005, Pages 1115-1123

  Kamath, Amrita V ^a   Morrison, Richard A ^a,b   Harper, Timothy W ^a   Lan, Shih Jung ^a   Marino, Anthony M ^a   Chong, Saeho ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioavailability; Oral absorption; P glycoprotein; Paracellular transport; Pharmacokinetics

Indexed keywords

APROTININ; BMS 262084; CEFALEXIN; CERANAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN P; INULIN; TRYPSIN; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CELL STRAIN CACO 2; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSPORT; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; MALE; NONHUMAN; RAT; TIGHT JUNCTION;

EID: 20344400420     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20278     Document Type: Article

References (23)

1. Rice KD, Tanaka RD, Katz BA, Numerof RP, Moore WR. 1998. Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des 4:381-396.
2. Schwartz L. 1994. Tryptase, a mast cell serine protease. Methods Enzymol 244:88-101.
3. Gangloff AR. 2000. Tryptase Inhibitors in the treatment of pulmonary diseases. Curr Opin Investig Drugs 1:79-85.
4. Button JC, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Slusarchyk WA, Treuner U, Zahler R, Zhao G, Bisacchi GS. 2002. Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett 12:3229-3233.
5. Gochoco CH, Ryan FM, Miller J, Smith PL, Hidalgo IJ. 1994. Uptake and transepithelial transport of the orally absorbed cephalosporin cephalexin, in the human intestinal cell line, Caco-2. Int J Pharm 104:187-202.
6. Friedman DI, Amidon GL. 1989. Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: Lisinopril and SQ 29,852. J Pharm Sci 78:995-998.
7. Nakashima E, Tsuji A, Mizuo H, Yamana T. 1984. Kinetics and mechanism of in vitro uptake of amino-beta-lactam antibiotics by rat small intestine and relation to the intact-peptide transport system. Biochem Pharmacol 33:3345-3352.
8. Tsuji A, Nakashima E, Kagami I, Yamana T. 1981. Intestinal absorption mechanism of amphoteric beta-lactam antibiotics I: Comparative absorption and evidence for saturable transport of amino-beta-lactam antibiotics by in situ rat small intestine. J Pharm Sci 70:768-772.
9. Marino AM, Chong S, Dando SA, Kripalani KJ, Bathala MS, Morrison RA. 1996. Distribution of the dipeptide transporter system along the gastrointestinal tract of rats based on absorption of a stable and specific probe, SQ-29852. J Pharm Sci 85:282-286.
10. Conradi RA, Burton PS, Borchardt RT. 1996. Physiochemical and biological factors that influence a drug's cellular permeability by passive diffusion. In: Pliska V, Testa B, van de Waterbeemd H, Mannhold R, Kubinyi H, Timmerman H, editors. Drug action and toxicology. New York: VCH Publishers, pp 233-252.
11. Sjostrom M, Lindfors L, Ungell AL. 1999. Inhibition of binding of an enzymatically stable thrombin inhibitor to lumenal proteases as an additional mechanism of intestinal absorption enhancement. Pharm Res 16:74-79.
12. Lundin PD, Lundin S, Olsson H, Karlsson BW, Westrom BR, Pierzynowski SG. 1995. Enhanced intestinal absorption of oxytocin peptide analogues in the absence of pancreatic juice in pigs. Pharm Res 12:1478-1482.
13. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. 1999. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther 288:171-178.
14. Cook MJ, Hirst BH. 1994. Transepithelial secretion of the histamine H-2 receptor antagonist ranitidine in human intestinal epithelial Caco-2 monolayers is mediated by P-glycoprotein. J Physiol (Lond.) 479P: 103.
15. Chan LM, Lowes S, Hirst BH. 2004. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51.
16. Gibaldi M, Perrier D. 1982. Pharmacokinetics. New York: Marcel Dekker, pp 409-417.
17. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
18. Gotoh S, Nakamura R, Nishiyama M, Fujita T, Yamamoto A, Muranishi S. 1995. Does bacitracin have an absorption-enhancing effect in the intestine? Biol Pharm Bull 18:794-796.
19. Gotoh S, Nakamura R, Nishiyama M, Quan YS, Fujita T, Yamamoto A, Muranishi S. 1996. Effects of protease inhibitors on the absorption of phenol red and fluorescein isothiocyanate dextrans from the rat intestine. J Pharm Sci 85:858-862.
20. Guyton AC. 1991. Textbook of medical physiology, 8th ed. Philadelphia: Prism & Saunders Co., pp. 718-720.
21. Collett A, Sims E, Walker D, He YL, Ayrton J, Rowland M, Warhurst G. 1996. Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res 13:216-221.
22. Artursson P, Ungell AL, Lofroth JE. 1993. Selective paracellular permeability in two models of intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 10:1123-1129.
23. Gottesman MM, Pastan I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.